Since the release of the first medium flux nanopore sequencer, PolyseqOne, in January 2024, Polyseq Biotechnology has had in-depth exchanges and sincere cooperation with its partners, carefully polishing product performance, user experience, and stability. Since last month, Polyseq Biotechnology has successively delivered to more than ten customers. Researcher Yu Yang from Guangzhou Women and Children's Medical Center, as a user of Polyseq Biotechnology's PolyseqOne 001 sequencing machine, has started to fully carry out scientific research applications on the PolyseqOne sequencing platform!
Delivery and signing ceremony for the first PolyseqOne
Researcher Yu Yang was invited to personally experience the PolyseqOne nanopore sequencing platform at Polyseq Biotechnology
The PolysseqOne sequencer is derived from the transformation of original scientific research achievements by the Institute of Biophysics, Chinese Academy of Sciences. Thanks to strong scientific research accumulation and suitable technical routes in the early stage, it adheres to independent innovation and has achieved multiple breakthrough results in the field of nanopore sequencing. Under the personal leadership of the founding scientist, various R&D departments of Polyseq Biotechnology promote high-speed research and development through interdisciplinary collision. Researchers and engineers from different disciplinary backgrounds collaborate to define the technical specifications of products and leverage their professional advantages in product design, manufacturing, and verification at various stages. At the same time, Polyseq Biotechnology has invested a lot of resources in technological innovation and process optimization to ensure a smooth transition of technology from laboratory scale to industrial scale. Resolve issues related to the stability of nanopores and their components, precise control of mass production processes, and compatibility and consistency of components. In the earnest expectations of our customers, we have completed the development of the sequencing machine in just 2 years since its establishment. Overcoming the difficulties of productization through highly open collaboration, the sequencing instrument was officially launched into the market in less than 3 years, achieving full platform localization of nanopore sequencing instruments and consumables in the shortest time and with the least cost. Polyseq Biotechnology is well aware that only by providing products with stable performance and excellent quality can we win the trust and satisfaction of customers. Therefore, Polyseq Biotechnology has established a strict comprehensive quality management system, covering every link from raw material procurement, production and manufacturing to product testing and after-sales service.
2024 is the first year of commercialization for PolyseqOne. Since the release of its first product in January this year, PolyseqOne has established a Market, Product, and Application Center, which is fully responsible for product optimization, application scenario development, market promotion, and new product definition. Based on market research results, the PolyseqOne sequencing platform and supporting components are all based on customer needs, customer feedback, and customer expectations, with a steady and steady pace of "taking small steps" to grasp product details, an extraordinary courage to "involve big rivers" to promote product innovation, a long-term thinking to plan product value, and will maintain a passion of "not letting go of any feedback, not ignoring any flaws" for a long time, so that every step is taken to ensure the success of the product. The sequencer delivered to the customer's hands is worth the price.
The first installed and running PolyseqOne nanopore sequencing platform SEQ ID: 10000001
Adhering to the principle of "putting troops before horses, food and supplies first", the technical support team of Polyseq is leading the way in product sales. The technical support team is selected and formed by technical elites. While ensuring a warm and responsible attitude, it has excellent knowledge reserves and problem-solving abilities. In addition to routine services such as installation, training, and after-sales, it also provides various additional support such as optimizing experimental methods and customizing sequencing processes.
The first officially delivered PolysseqOne has been running smoothly in YUlab, mainly used for whole genome sequencing, transcriptome sequencing, transposon element detection and other directions in fruit flies and mice. Currently, the average effective sequencing unit of a single PolysseqCell chip is>1200, and the average output data is 15G. The accuracy of sequencing data compared with genome databases has shown advantages, and the read length distribution is also comparable to other sequencing platforms.
In order to achieve long-term development, Polyseq Biotechnology deeply understands the importance of working hand in hand with partners. The company will continue to deepen cooperation with enterprises, research institutes, universities, and medical institutions to jointly explore new fields of gene sequencing technology and promote the transformation of scientific research achievements. Polyseq Biotechnology also looks forward to establishing strategic partnerships with domestic and foreign peers, enhancing the overall competitiveness of the industry through resource sharing and complementary advantages.
